IMMUNIC INC IMUX 深 滬
等待開盤 08-21 09:30:00 美东时间
16.10
-0.350
-2.13%
華盛通- 最 高16.67
- 今 開16.39
- 成交量 20.08万股
- 最 低 15.92
- 昨 收 16.45
- 總市值 2.20亿
- 52周最高 17.43
- 市盈率 靜 --
- 換手率 1.47%
- 52周最低 5.062
- 委 比 36.99%
- 總股本 1364.45万
- 歷史最高 289.90
- 量 比 1.23
- 振 幅 4.56%
- 歷史最低 5.062
- 每 手 1
- 風險率 3.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45
Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.
08-17 21:08
Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 60 percent increase over losses of $(2.00) per share from the same period last year.
08-11 18:36
Immunic Appoints Elena Ridloff to Board of Directors
– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis a...
08-11 04:05
Immunic Names CEO Erik Lundgren to Board
Immunic ( ($IMUX) ) has issued an announcement. On June 29, 2026, Immunic direc...
07-07 04:45
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic's Phase 3 trials in 2026.
05-27 18:17
B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27
B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.
05-22 22:16
Immunic Appoints Michael W. Bonney As Board Chairman
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
